64x Bio Launches AAV Apex Suite to Tackle Gene Therapy Manufacturing Bottlenecks

• 64x Bio has launched AAV Apex Suite, a high-yield product line aimed at improving adeno-associated virus (AAV) manufacturing.

• The company reports strategic collaborations with five global biopharma and CDMO partners to evaluate the new suite.

64x Bio, a biotechnology company focused on scalable manufacturing solutions for advanced therapies, has announced the launch of its AAV Apex Suite. The new product line is designed to address critical manufacturing challenges in gene therapy by increasing viral vector yield and quality.

The AAV Apex Suite includes suspension-adapted HEK293 cell lines for transient transfection and production processes that consistently deliver titers exceeding E15 vector genomes per litre. According to the company, product performance has been independently validated across a range of serotypes and therapeutic payloads.

The suite leverages 64x Bio’s VectorSelect platform, which combines genetic and metabolic data to enhance cell line engineering and media formulations. “Our team has done incredible work to develop AAV Apex Suite as an initial demonstration of what our platform can achieve,” said Lexi Rovner, PhD, CEO and Co-founder of 64x Bio.

Five global biopharma and CDMO organisations have already entered strategic collaborations to evaluate the suite. While the current offering supports transient production, stable cell lines are in development, with further tools to be introduced as the suite evolves.

64x Bio also partners with developers to create custom manufacturing solutions via VectorSelect, with plans to expand into advanced biologics beyond AAV.